Hocoma AG Release: Andago - The First Of Its Kind Mobile Robot For Rehabilitation Is Now Available In U.S.A.

The newest member of the Hocoma robotic device family, Andago®, is commercially available in USA now.

NORWELL, Mass.--(BUSINESS WIRE)--Andago is the first of its kind mobile robot opening up new perspectives in functional gait therapy with dynamic body-weight support. Andago provides safe, mobile and versatile training on the way back to independent living.

“We are excited to make the Andago available to the US market”

The first Andago in the United States was purchased by Moss Rehab in Pennsylvania. With 17 medical robots installed, Moss Rehab is currently the largest user of such devices in the country.

“The Andago offers flexibility and ease of use and I like its versatility, which should allow us to optimally prepare our patients for the wide variety of environments and challenges they need to master in everyday activities,” Moss Rehab’s Chief Medical Officer, Dr. Alberto Esquenazi says about the main advantages of the Andago.

Dr. Esquenazi points out that it will enable patients who have had a stroke or a traumatic brain injury to move more quickly from supported or assisted gait to unsupported walking. It also enables one therapist to work with a patient instead of the two or three who are required with other techniques.

“We are excited to make the Andago available to the US market,” says Frank Menzler, Executive Vice President of Hocoma North America. “Andago allows upright, hands-free walking without spatial limitations. It bridges the gap between treadmill-based gait training and free walking, and offers a safe and functional environment.”

Video links:

https://youtu.be/7OZGt_jC8kM

Press images

www.hocoma.com/de/mediencenter/pressebilder/

About Hocoma

A successful therapy begins in patients’ heads. In the firm belief that – step by step – they can reach their goals and regain quality of life.

This is what we work for at the Swiss medtech company Hocoma. With technologies and ideas that look at functional movement therapy from a completely different angle. Because they enable independent exercises and create maximum motivation. Because they challenge people to take courage and support their hopes with personal achievements.

We are committed to creating the ideal therapy. Our awarded robotic and sensor-based devices offer solutions for intensive gait therapy (Lokomat®, Andago®), functional therapy of the upper extremities (Armeo®), robotic mobilization and functional electrical stimulation in early rehabilitation (Erigo®) as well as functional movement therapy within low back pain treatment (Valedo® Therapy Concept) at home and at the clinic. They are the result of intensive research, consistent development and continuous exchange with patients, therapists and partners in research and science.

Those who see to break new grounds need to stay open to exceptional ideas. They have the potential of being exceptionally effective. This guiding principle by Hocoma founder and CEO Dr. Gery Colombo has accompanied us since our start in 2000 and is still lived and implemented by our dedicated employees around the world. At the headquarters in Volketswil near Zurich (Switzerland) and the subsidiaries in the USA, Singapore and Slovenia they achieved a turnover of more than 30 million CHF in 2014.

Product Disclaimer

All Hocoma products are medical devices and must be used in strict adherence to the User Manual; failure to do so may result in serious personal injury. It is strongly recommended that you regularly consult Hocoma’s website (www.hocoma.com/legalnotes) for the latest available information. Please contact Hocoma in case of any questions.

Use only under the supervision of qualified medical personnel. However, certain Hocoma products are marketed for home use and must be strictly used according to the recommendations of your medical care provider who is knowledgeable about your specific needs. Consult the User Manual and Hocoma’s website (www.hocoma.com/legalnotes) for appropriate product designation. Failure to obtain and follow the recommendations of your medical care provider may result in serious personal injury.

This information provides details about medical products which may not be available in all countries and may not have received approval or market clearance by all governmental regulatory bodies throughout the world. Nothing herein should be construed as a solicitation or promotion of any product or of an indication of any specific use for any product which is not authorized by the laws and regulations of the country where the reader of this information resides.